ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
Alnylam Pharmaceuticals, Inc. - Common Stock について Wikipediaからの企業概要
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
続きを読む
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
History
The company is a spin-off from the Max Planck Institute for Biophysical Chemistry. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders, and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy. In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
On October 10, 2018, Alnylam appoints Margaret Hamburg to Board of Directors. Prior to this, from May 2009 to April 2015, she serves as Commissioner of the U.S. Food and Drug Administration (FDA).
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.
In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.
In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.
Products
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.
Patisiran
In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).
In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
FDA on patisiran for cardiomyopathy
In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA. The committee meeting chose to deny approval for the treatment of cardiomyopathy of ATTR amyloidosis with patisiran. Note that while patisiran was denied for the indication of cardiomyopathy, it remains an FDA approved treatment for polyneuropathy.
Vutrisiran
Alnylam went on to pursue the development of vutrisiran, which received FDA approval in 2022 and accounted for the majority of reported profit compared to patisiran/Onpattro in 2025.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
ALNY 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
ALNY 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
ALNY アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
- 強い買い 8 21.6%
- 買い 21 56.8%
- 保有 8 21.6%
- 売り 0 0.0%
- 強い売り 0 0.0%
12ヶ月目標株価
26 アナリスト · 2026-08-21決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
| 期間 | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|
| 2026年6月30日 | $1.21 | $1.59 | -0.38% |
| 2026年3月31日 | $1.51 | $0.98 | 0.53% |
| 2025年12月31日 | $0.82 | $1.15 | -0.33% |
| 2025年9月30日 | $2.11 | $0.76 | 1.3% |
| 2025年6月30日 | $-0.51 | $-0.73 | 0.22% |
| 2025年3月31日 | $-0.44 | $-1.03 | 0.59% |
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書 17
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
貸借対照表 23
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
キャッシュフロー 14
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
収益性 7
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
流動性と支払能力 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
効率性 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
成長率 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM） 10
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
損益計算書 17
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
貸借対照表 22
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
キャッシュフロー 12
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
収益性 7
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
流動性と支払能力 3
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
効率性 3
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
バリュエーション（TTM） 10
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
損益計算書
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 収益 | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| 営業利益率 % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| 純利益 | $314M | $-278M | $-440M | $-1.13B | $-853M |
| 希薄化後EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
貸借対照表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流動比率 | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| クイックレシオ | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
キャッシュフロー
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $465M | $-43M | $42M | $-613M | $-718M |
最新ニュース この会社に言及した最近の見出し
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
あなたにとって重要なメトリクスを選択 — 上記の決算詳細の任意の行の横にある➕をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
機関投資家（13F） 877 提出者 · $27.2B合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 92 (-24 前期比) | 77 (-68 前期比) | 336 (+11 前期比) | 263 (+7 前期比) | +2.3M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| Capital World Investors | $3,354,715,611 | 11,144,846 | 12.36% | 株式数 |
| FMR LLC | $3,108,157,652 | 10,325,076 | 11.45% | 株式数 |
| Capital Research Global Investors | $2,935,115,324 | 9,750,699 | 10.81% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,968,251,542 | 6,538,390 | 7.25% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,815,053,762 | 6,029,478 | 6.69% | 株式数 |
| STATE STREET CORP | $1,070,369,060 | 3,555,689 | 3.94% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $686,853,582 | 2,288,725 | 2.53% | 株式数 |
| NORGES BANK | $683,883,867 | 2,271,813 | 2.52% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $614,923,915 | 2,042,733 | 2.26% | 株式数 |
| Dodge & Cox | $588,631,955 | 1,955,393 | 2.17% | 株式数 |
| TWO SIGMA INVESTMENTS, LP | $564,713,315 | 1,875,937 | 2.08% | 株式数 |
| AMERICAN CENTURY COMPANIES INC | $558,098,292 | 1,853,956 | 2.06% | 株式数 |
| TWO SIGMA ADVISERS, LP | $450,362,484 | 1,132,560 | 1.66% | 株式数 |
| Clearbridge Investments, LLC | $379,142,285 | 1,259,483 | 1.40% | 株式数 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269,059,154 | 893,795 | 0.99% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $259,723,265 | 862,782 | 0.96% | 株式数 |
| Deep Track Capital, LP | $248,349,750 | 825,000 | 0.91% | 株式数 |
| Qube Research & Technologies Ltd | $240,437,176 | 798,715 | 0.89% | 株式数 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219,642,021 | 729,635 | 0.81% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $176,408,397 | 586,016 | 0.65% | 株式数 |
| LOOMIS SAYLES & CO L P | $170,456,431 | 566,244 | 0.63% | 株式数 |
| BAILLIE GIFFORD & CO | $165,849,468 | 550,940 | 0.61% | 株式数 |
| ROYAL BANK OF CANADA | $154,998,000 | 514,893 | 0.57% | 株式数 |
| Polar Capital Holdings Plc | $145,322,534 | 482,751 | 0.54% | 株式数 |
| Paradigm Biocapital Advisors LP | $144,494,400 | 480,000 | 0.53% | 株式数 |
| D. E. Shaw & Co., Inc. | $129,533,209 | 430,300 | 0.48% | コールオプション |
| FIRST TRUST ADVISORS LP | $126,894,361 | 421,534 | 0.47% | 株式数 |
| Swiss National Bank | $112,609,302 | 374,080 | 0.41% | 株式数 |
| WELLS FARGO & COMPANY/MN | $111,381,100 | 370,000 | 0.41% | コールオプション |
| BlackRock, Inc. | $102,807,465 | 341,519 | 0.38% | 株式数 |
| CANADA PENSION PLAN INVESTMENT BOARD | $100,618,073 | 334,246 | 0.37% | 株式数 |
| Sumitomo Mitsui Trust Group, Inc. | $97,948,840 | 325,379 | 0.36% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97,804,647 | 324,900 | 0.36% | コールオプション |
| Legal & General Group Plc | $97,467,493 | 323,780 | 0.36% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $95,125,781 | 316,001 | 0.35% | 株式数 |
| DIMENSIONAL FUND ADVISORS LP | $94,687,695 | 314,546 | 0.35% | 株式数 |
| Candriam S.C.A. | $94,586,456 | 314,512 | 0.35% | 株式数 |
| D. E. Shaw & Co., Inc. | $93,229,593 | 309,702 | 0.34% | 株式数 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90,367,000 | 300,193 | 0.33% | 株式数 |
| DEUTSCHE BANK AG\ | $89,849,026 | 298,472 | 0.33% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88,641,294 | 294,460 | 0.33% | 株式数 |
| Pictet Asset Management Holding SA | $83,257,214 | 278,613 | 0.31% | 株式数 |
| BNP PARIBAS FINANCIAL MARKETS | $81,586,054 | 271,023 | 0.30% | 株式数 |
| GILDER GAGNON HOWE & CO LLC | $80,992,374 | 269,051 | 0.30% | 株式数 |
| CONGRESS ASSET MANAGEMENT CO | $79,983,972 | 265,701 | 0.29% | 株式数 |
| VANGUARD ASSET MANAGEMENT, Ltd | $77,578,441 | 257,710 | 0.29% | 株式数 |
| California Public Employees Retirement System | $76,477,575 | 254,053 | 0.28% | 株式数 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75,974,872 | 252,383 | 0.28% | 株式数 |
| Korea Investment CORP | $74,553,090 | 247,660 | 0.27% | 株式数 |
| Woodline Partners LP | $74,138,270 | 246,282 | 0.27% | 株式数 |
| Squarepoint Ops LLC | $70,440,719 | 233,999 | 0.26% | 株式数 |
| TD Asset Management Inc | $70,349,507 | 233,696 | 0.26% | 株式数 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65,136,061 | 196,863 | 0.24% | 株式数 |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64,296,696 | 213,589 | 0.24% | 株式数 |
| National Pension Service | $59,692,744 | 198,295 | 0.22% | 株式数 |
| PINEBRIDGE INVESTMENTS LLC | $58,914,280 | 195,709 | 0.22% | 株式数 |
| Robeco Institutional Asset Management B.V. | $56,618,929 | 188,084 | 0.21% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53,824,164 | 178,800 | 0.20% | プットオプション |
| VICTORY CAPITAL MANAGEMENT INC | $52,030,628 | 172,842 | 0.19% | 株式数 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50,772,924 | 168,664 | 0.19% | 株式数 |
| RHUMBLINE ADVISERS | $49,844,185 | 165,579 | 0.18% | 株式数 |
| Life Cycle Investment Partners Ltd | $49,797,587 | 165,424 | 0.18% | 株式数 |
| ANTIPODES PARTNERS Ltd | $49,228,339 | 163,533 | 0.18% | 株式数 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47,228,883 | 157,223 | 0.17% | 株式数 |
| CAPITAL FUND MANAGEMENT S.A. | $46,931,781 | 155,904 | 0.17% | 株式数 |
| Assenagon Asset Management S.A. | $46,868,866 | 155,695 | 0.17% | 株式数 |
| Vinva Investment Management Ltd | $45,487,381 | 154,972 | 0.17% | 株式数 |
| JANUS HENDERSON GROUP PLC | $43,671,202 | 132,000 | 0.16% | 株式数 |
| Hudson Bay Capital Management LP | $42,204,406 | 140,200 | 0.16% | 株式数 |
| ENVESTNET ASSET MANAGEMENT INC | $41,059,106 | 136,395 | 0.15% | 株式数 |
| ProShare Advisors LLC | $38,686,569 | 128,514 | 0.14% | 株式数 |
| GOLDMAN SACHS GROUP INC | $37,029,700 | 123,010 | 0.14% | 株式数 |
| LMR Partners LLP | $35,881,572 | 119,196 | 0.13% | 株式数 |
| Man Group plc | $35,798,187 | 118,919 | 0.13% | 株式数 |
| HSBC HOLDINGS PLC | $35,754,282 | 120,600 | 0.13% | プットオプション |
| SCS Capital Management LLC | $34,783,715 | 115,549 | 0.13% | 株式数 |
| AVIVA PLC | $34,477,568 | 114,532 | 0.13% | 株式数 |
| Davern Capital Partners, LP | $34,041,978 | 113,085 | 0.13% | 株式数 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33,770,750 | 112,184 | 0.12% | 株式数 |
| Longaeva Partners L.P. | $33,191,869 | 110,261 | 0.12% | 株式数 |
| 683 Capital Management, LLC | $32,360,725 | 107,500 | 0.12% | プットオプション |
| MARSHALL WACE, LLP | $32,215,929 | 107,019 | 0.12% | 株式数 |
| HighTower Advisors, LLC | $31,621,666 | 105,045 | 0.12% | 株式数 |
| Bridgewater Associates, LP | $29,977,772 | 99,584 | 0.11% | 株式数 |
| Prosight Management, LP | $29,525,022 | 98,080 | 0.11% | 株式数 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28,956,123 | 96,408 | 0.11% | 株式数 |
| Andra AP-fonden | $28,685,436 | 86,697 | 0.11% | 株式数 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28,376,894 | 94,266 | 0.10% | 株式数 |
| AMERIPRISE FINANCIAL INC | $28,191,159 | 93,649 | 0.10% | 株式数 |
| BARCLAYS PLC | $27,979,234 | 92,945 | 0.10% | 株式数 |
| TREMBLANT CAPITAL GROUP | $27,977,728 | 92,940 | 0.10% | 株式数 |
| FIL Ltd | $27,652,616 | 91,860 | 0.10% | 株式数 |
| Balyasny Asset Management L.P. | $26,945,195 | 89,510 | 0.10% | 株式数 |
| Caisse de depot et placement du Quebec | $25,812,720 | 85,748 | 0.10% | 株式数 |
| Mitsubishi UFJ Trust & Banking Corp | $24,911,136 | 82,753 | 0.09% | 株式数 |
| RAYMOND JAMES FINANCIAL INC | $24,661,883 | 81,925 | 0.09% | 株式数 |
| CITADEL ADVISORS LLC | $24,564,048 | 81,600 | 0.09% | コールオプション |
| VANGUARD GROUP INC | $24,356,460 | 61,251 | 0.09% | 株式数 |
| NEOS Investment Management LLC | $23,562,822 | 78,274 | 0.09% | 株式数 |
| JONES FINANCIAL COMPANIES LLLP | $23,444,213 | 80,462 | 0.09% | 株式数 |
企業インサイダー 41 人のインサイダー · 1人の役員 · 13人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | 2026年4月6日 S | 9,443 | 0 | 14 | $-1,274,343 |
| Colleen F Reitan | 取締役 | 2026年5月20日 A | 1,446 | 0 | 0 | $0 |
| Charles Elliott Sigal | 取締役 | 2026年5月20日 A | 1,446 | 0 | 0 | $0 |
| Stuart A Arbuckle | 取締役 | 2026年5月20日 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | 取締役 | 2026年5月20日 A | 1,446 | 0 | 0 | $0 |
| Amy Schulman | 取締役 | 2026年5月20日 A | 24,049 | 0 | 0 | $0 |
| Dennis A Ausiello | 取締役 | 2026年5月20日 A | 1,582 | 0 | 0 | $0 |
| Margaret A Hamburg | 取締役 | 2026年5月20日 A | 1,582 | 0 | 0 | $0 |
| KELLOGG PETER N | 取締役 | 2026年5月20日 A | 1,446 | 0 | 0 | $0 |
| David E I Pyott | 取締役 | 2026年5月20日 A | 1,582 | 0 | 0 | $0 |
| Victor J Dzau | 取締役 | 2012年6月21日 A | — | 0 | 0 | $0 |
| Peter Barrett | 取締役 | 2006年6月1日 A | 5,293 | 0 | 0 | $0 |
| John E Berriman | 取締役 | 2005年6月8日 A | 2,475 | 0 | 0 | $0 |
| Christoph H Westphal | 取締役 | 2004年6月3日 C | 2,409,970 | 0 | 0 | $0 |
| Sanofi | 10%オーナー | 2017年5月31日 P | 10,554,134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | 10%オーナー | 2016年2月23日 S | 4,896,716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | 10%オーナー | 2004年6月3日 C | 2,409,970 | 0 | 0 | $0 |
| CHP II LP | 10%オーナー | 2004年5月27日 P | 232,500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | 2018年8月10日 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | 2018年8月10日 A | 9,030 | 0 | 0 | $0 |
| John Maraganore | — | 2018年8月10日 A | 151,297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | 2018年3月9日 M | 140,795 | 0 | 0 | $0 |
| Michael Mason | — | 2018年1月4日 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | 2017年12月29日 M | 14,500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | 2017年12月20日 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | 2016年12月20日 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 2015年11月19日 G | 306,996 | 0 | 0 | $0 |
| Marsha Fanucci | — | 2015年6月1日 A | 10,000 | 0 | 0 | $0 |
| Steven M Paul | — | 2015年6月1日 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | 2015年6月1日 A | — | 0 | 0 | $0 |
| John K Clarke | — | 2015年6月1日 A | 2,091,868 | 0 | 0 | $0 |
| Kevin P Starr | — | 2015年6月1日 A | — | 0 | 0 | $0 |
| Laurence Reid | — | 2014年5月19日 M | 3,905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | 2010年12月8日 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | 2010年12月8日 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | 2010年6月18日 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | 2010年6月2日 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | 2009年6月11日 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | 2008年12月9日 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | 2005年12月7日 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | 2004年6月3日 C | 18,745 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
アクティビストおよび5%超のオーナー 2保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 提出書類 | 2007年2月14日 | — | 初回提出 | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | 2006年2月15日 | — | 初回提出 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF保有状況 158のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 3.27% | 56,843 SH | 2026年8月21日 | 日次 |
| NUMG · Nushares ETF Trust | 3.23% | 36,910 NS | 2026年4月30日 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3.19% | 10,523 NS | 2026年5月31日 | N-PORT |
| FMED · Fidelity Covington Trust | 2.79% | 3,791 NS | 2026年5月31日 | N-PORT |
| FBT · First Trust Exchange-Traded Fund | 2.52% | 235,602 NS | 2026年6月30日 | N-PORT |
| IBB · iShares Trust | 2.15% | 994,103 SH | 2026年8月21日 | 日次 |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2.01% | 3,468 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 2.01% | 4,904 NS | 2026年5月31日 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1.97% | 7,857 SH | 2026年8月21日 | 日次 |
| QQEW · First Trust Exchange-Traded Fund | 1.96% | 117,806 NS | 2026年6月30日 | N-PORT |
| FDG · AMERICAN CENTURY ETF TRUST | 1.94% | 26,515 NS | 2026年5月31日 | N-PORT |
| QQXT · First Trust Exchange-Traded Fund | 1.86% | 10,248 NS | 2026年6月30日 | N-PORT |
| JMID · Janus Detroit Street Trust | 1.40% | 824 NS | 2026年4月30日 | N-PORT |
| CAML · Professionally Managed Portfolios | 1.29% | 15,623 NS | 2026年4月30日 | N-PORT |
| BBP · ETFis Series Trust I | 1.24% | 2,379 NS | 2026年4月30日 | N-PORT |
| HRTS · Tema ETF Trust | 1.14% | 1,954 NS | 2026年5月31日 | N-PORT |
| MEDI · Harbor ETF Trust | 1.08% | 966 NS | 2026年4月30日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.90% | 15,151 NS | 2026年4月30日 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0.89% | 35,072 NS | 2026年4月30日 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0.88% | 1,022,888 SH | 2026年8月19日 | 日次 |
| IWP · iShares Trust | 0.86% | 768,270 SH | 2026年8月21日 | 日次 |
| JOET · Virtus ETF Trust II | 0.80% | 6,062 NS | 2026年4月30日 | N-PORT |
| CGGR · Capital Group Growth ETF | 0.76% | 613,330 NS | 2026年5月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.66% | 60,901 NS | 2026年4月30日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.59% | 398,693 SH | 2026年8月19日 | 日次 |
| FFLG · FIDELITY COVINGTON TRUST | 0.58% | 11,032 NS | 2026年4月30日 | N-PORT |
| QNXT · iShares Trust | 0.55% | 699 SH | 2026年8月21日 | 日次 |
| USMV · iShares Trust | 0.50% | 521,451 SH | 2026年8月21日 | 日次 |
| IYH · iShares Trust | 0.47% | 79,594 SH | 2026年8月21日 | 日次 |
| VXF · VANGUARD INDEX FUNDS | 0.45% | 1,532,109 SH | 2026年8月19日 | 日次 |
| UPSD · ETF Series Solutions | 0.44% | 1,435 NS | 2026年4月30日 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0.43% | 4,118 NS | 2026年5月31日 | N-PORT |
| FTXH · First Trust Exchange-Traded Fund VI | 0.42% | 510 NS | 2026年6月30日 | N-PORT |
| IMCG · iShares Trust | 0.41% | 73,113 SH | 2026年8月21日 | 日次 |
| QFLR · Innovator ETFs Trust | 0.39% | 6,430 NS | 2026年4月30日 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0.39% | 2,893,468 SH | 2026年8月19日 | 日次 |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.38% | 10,723 NS | 2026年4月30日 | N-PORT |
| ESMV · iShares Trust | 0.37% | 128 SH | 2026年8月21日 | 日次 |
| CVMC · Morgan Stanley ETF Trust | 0.37% | 1,248 NS | 2026年6月30日 | N-PORT |
| SDG · iShares Trust | 0.34% | 2,658 SH | 2026年8月21日 | 日次 |
| SMIZ · Zacks Trust | 0.31% | 2,688 NS | 2026年5月31日 | N-PORT |
| ESLG · Strategy Shares | 0.31% | 196 NS | 2026年4月30日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.31% | 112 NS | 2026年4月30日 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.30% | 305 NS | 2026年4月30日 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.28% | 94 NS | 2026年5月31日 | N-PORT |
| HQGO · Lattice Strategies Trust | 0.26% | 404 NS | 2026年4月30日 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0.24% | 2,252 NS | 2026年4月30日 | N-PORT |
| ESUM · Strategy Shares | 0.23% | 1,141 NS | 2026年4月30日 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0.23% | 45,231 NS | 2026年4月30日 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.22% | 15,559 NS | 2026年4月30日 | N-PORT |